AbbVie stock slides 2.23% and underperforms competitors
Updated
Updated · MarketWatch · May 1
AbbVie stock slides 2.23% and underperforms competitors
8 articles · Updated · MarketWatch · May 1
Shares closed at $206.60 on Friday, as the S&P 500 rose 0.29% to 7,230.12 while the Dow Jones Industrial Average fell 0.31% to 49,499.27.
The decline ended a three-day winning streak and left AbbVie 15.61% below its 52-week high of $244.81 reached on 1 October.
Among peers, Johnson & Johnson fell 1.16%, Pfizer lost 1.39% and Amgen dropped 4.75%, leaving AbbVie weaker than some rivals but not the sector's steepest faller.
AbbVie's earnings soared, but its stock fell. Is its promising drug pipeline hitting a hidden wall?
Analysts call AbbVie's stock undervalued, but its valuation is sky-high. What is the company's real worth?